KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study

被引：6
|
作者：
Bassetti, Matteo [1 ,2 ]
Carannante, Novella [3 ]
Pallotto, Carlo [3 ,4 ]
Righi, Elda [1 ,2 ]
Di Caprio, Giovanni [5 ]
Bernardo, Mariano [6 ]
Sodano, Giuseppe [6 ]
Mallardo, Enza [6 ]
Francisci, Daniela [4 ]
Sartor, Assunta [1 ,2 ]
Graziano, Elena [1 ,2 ]
Tascini, Carlo [3 ]
机构：
[1] Univ Udine, Dept Med, Infect Dis Div, Piazzale Santa Maria Misericordia 15, Udine, Italy
[2] Santa Maria Misericordia Univ Hosp, Piazzale Santa Maria Misericordia 15, Udine, Italy
[3] AORN Colli, Cotugno Hosp, Div Infect Dis 1, Via G Quagliariello 51, I-80131 Naples, Italy
[4] Univ Perugia, Dept Med, Infect Dis Sect, Piazzale Gambuli 1, Perugia, Italy
[5] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Publ Med, Infect Dis Sect, Naples, Italy
[6] AORN Colli, Cotugno Hosp, Microbiol & Virol Unit, Via G Quagliariello 51, Naples, Italy
来源：
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE | 2019年 / 17卷
关键词：
Carbapenemase-producing Klebsiella pneumoniae; KPC; Ceftazidime/avibactam; Ceftazidime; Gut decolonisation; ORAL GENTAMICIN; RESISTANT; DECONTAMINATION; INFECTIONS; COLONIZATION; ERADICATION;
D O I：
10.1016/j.jgar.2018.11.014
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Objectives: KPC-producing Klebsiella pneumoniae (KPC-Kp) gut colonisation is a major risk factor for developing systemic infection. Ceftazidime/avibactam (CAZ/AVI) may have a role as decolonisation therapy in special situations. Methods: This was a retrospective, observational, multicentre study. The KPC-Kp gut decolonisation rate of CAZ/AVI-based therapy (Group A) was compared with other antimicrobial regimens (Group B) in patients with KPC-Kp infection. Results: Among 12 patients in Group A, 11 (91.7%) achieved gut decolonisation. None of the 24 patients of Group B were decolonised. Conclusion: CAZ/AVI-based therapy could be useful in KPC-Kp gut decolonisation in high-risk patients. (C) 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：109 / 111
页数：3
相关论文
共 50 条
  • [1] In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam-based therapies
    Amadesi, Stefano
    Amedeo, Alberto
    Rinaldi, Matteo
    Palombo, Marta
    Giannella, Maddalena
    Gaibani, Paolo
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2024, 110 (01)
  • [2] In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
    Huang, Yanqin
    Wu, Tiffany
    Perez, Omar
    Rana, Amisha P.
    Chen, Liang
    Kreiswirth, Barry N.
    Satlin, Michael J.
    Bulman, Zackery P.
    FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [3] Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study
    Campogiani, Laura
    Vitale, Pietro
    Lodi, Alessandra
    Imeneo, Alessandra
    Fontana, Carla
    D'Agostini, Cartesio
    Compagno, Mirko
    Coppola, Luigi
    Spalliera, Ilaria
    Malagnino, Vincenzo
    Teti, Elisabetta
    Iannetta, Marco
    Andreoni, Massimo
    Sarmati, Loredana
    ANTIBIOTICS-BASEL, 2023, 12 (05):
  • [4] The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae
    Zhang, Xiaotuan
    Zeng, Weiliang
    Kong, Jingchun
    Huang, Zeyu
    Shu, Hongyun
    Tang, Miran
    Qian, Changrui
    Xu, Chunquan
    Zhou, Tieli
    Ye, Jianzhong
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (08) : 1865 - 1876
  • [5] Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients
    Gaibani, Paolo
    Bovo, Federica
    Bussini, Linda
    Bartoletti, Michele
    Lazzarotto, Tiziana
    Viale, Pierluigi
    Pea, Federico
    Ambretti, Simone
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (05) : 654.e1 - 654.e4
  • [6] Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae
    Tam, Vincent H.
    Merlau, Paul R.
    Hudson, Cole S.
    Kline, Ellen G.
    Eales, Brianna M.
    Smith, James
    Sofjan, Amelia K.
    Shields, Ryan K.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (11) : 3130 - 3137
  • [7] Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments
    Gaibani, Paolo
    Bovo, Federica
    Bussini, Linda
    Lazzarotto, Tiziana
    Amadesi, Stefano
    Bartoletti, Michele
    Viale, Pierlugi
    Ambretti, Simone
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (06) : 1570 - 1577
  • [8] In vitro synergistic activity of meropenem/vaborbactam in combination with ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae
    Gaibani, Paolo
    Ambretti, Simone
    Viale, PierLuigi
    Re, Maria Carla
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (05) : 1457 - 1459
  • [9] In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae
    Romanelli, Federica
    De Robertis, Annalisa
    Carone, Gianluca
    Dalfino, Lidia
    Stufano, Monica
    Del Prete, Raffaele
    Mosca, Adriana
    NEW MICROBIOLOGICA, 2020, 43 (03): : 136 - 138
  • [10] Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy
    Boattini, Matteo
    Bianco, Gabriele
    Charrier, Lorena
    Comini, Sara
    Iannaccone, Marco
    Almeida, Andre
    Cavallo, Rossana
    De Rosa, Francesco Giuseppe
    Costa, Cristina
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2023, 42 (04) : 431 - 439
12345